Philip, on Friday Katie Couric covered it on the CBS evening news, complete with a bi-polar patient who gained significant weight on Zyprexa, and an excerpt from that popular youtube clip from a former Lily drug rep turned whistleblower.

Google search shows that I have made about 70,000 Zyprexa ' whistle-blowing' pages over 4 years AND I took the stuff pre-black label 1996-2000 got type two diabetes which will shorten my life.

I don't get a dime! Amazing

Daniel Haszard

Related to your post regarding those bought by others:
Press Release: A Well Designed Sales Pitch?

Those who release and create press releases, that are intended to offer information that is authentic and newsworthy, are possibly in collusion with various sources of the mass media who receive these announcements from others with commercial interests in mind, and instruct such media outlets with mandated authoritarian nuances, such as the press release that they created will be void of alteration of any kind of their press release as directed to the receiver by the creator and sponsor of such press releases. The sponsoring organization that composes press releases does so in order to promote their organization and its products, and this much is rather clear.
These well- constructed statements are meticulously composed and customized before they are issued to targeted editors for mass media publication at select locations and times of release by this sponsor. As this is done, the mass media outlets are again instructed on how to present their completed statements, as well as are given instructions once again not to alter these press releases in any way, others have said frequently.
Press releases are a form of public relations often utilized for those companies who create what is supposed to be an attempt to express their products that they wish to convince readers that such products are innovative or newsworthy. Press releases, historically, have been created and released to inform the readers by adding insight and related information for them regarding a particular topic that was typically complete and balanced. Today, they seem to be more or less an annotative commercial with press releases generated by corporations in particular, so it seems.
Unfortunately, and presently, press releases are often embellished, biased, and incomplete with deliberate intent in order to benefit the creator of these documents, who again develops them solely to increase awareness and usage of their products that they promote with their business, which they want to be viewed as favorable with a positive image to the public. One could suggest that the mass media who receives these press releases are transformed into mass front groups who perhaps coercively offer third party legitimacy for the content of the press release as they release this information to their readers.
The often notable if not intentional flaws at times are numerous within such press releases that reflect reckless disregard for the readers, the American Public, who believe that what they are reading is honest and complete. This, however, is not the case is certain situations.
An example is an anonymous and anonymous press release posted on the Medical News Today website (www.medicalnewstoday.com) that is dated in March of 2006. The title: "Cymbalta Safely and Effectively Treats core anxiety symptoms associated with generalized anxiety disorder." Clearly, this title itself includes words associated with relief or elation, which are subjective and not objective elements which would clearly be more appropriate, according to some, if the press release was created to inform the reader, one could say.
The first paragraph of this press release repeats the results mentioned in the title of this article, but also states Cymbalta offers relief of painful symptoms associated with anxiety, as well as improved functional impairment- also claimed to be associated with anxiety in this press release. These conclusions are speculative at best, as these inferences appear to be unexamined by others regarding the benefits claimed to exist with Cymbalta as illustrated in this press release.
Cymbalta was not approved by the FDA for anxiety or any of the symptoms associated with this condition at the time of this press release. In fact, Cymbalta was not filed with the FDA for this speculated new indication for anxiety that was desired by Eli Lilly until May of 2006. By definition, this press release may possibly be off-label promotion as well as misbranding of Cymbalta that was performed overtly in this manner of the press release, one may speculate.
As one continues to read this press release, testimonials were intentionally created and inserted into this press release that illustrated results they hope are impactful to the reader regarding Cymbalta. This testimonial was from the lead author, who expanded the claims made initially with utilizing various medical terms, which was followed by this person’s passionate optimism about the great potential of Cymbalta based on this remarkable study.
This study, by the way, was to be addressed in further detail at a National Anxiety meeting some weeks after this press release was announced to the public on this website. The second testimonial was Eli Lilly's Medical Advisor expressing his elation about what the lead author just stated, followed by how much he was encouraged by these results that will benefit so many others that have these debilitating medical conditions. Of course, profit forecasts regarding Cymbalta remarkably were not stated in this press release.
What is not included in this particular press release was any clear statements regarding the disadvantages and adverse if not toxic events associated those who take Cymbalta. Reactions from Cymbalta users include discontinuation syndrome at times, when the user stops taking this medication, which I understand can be quite devastating for the one experiencing this syndrome. Furthermore acts of suicide and suicidal ideation have been frequently associated with those who take Cymbalta as well. There have been apparent lack of efficacy suggestions by others who have taken Cymbalta. Basically, anything that may be considered negative aspects about this drug were not annotated in this particular press release as it should have been for fair balance that is standard in the pharmaceutical industry and health care journalism. The staff involved with the release and publication of such press releases as this one described should perhaps be more informed on what not to accept and what to present regarding these issues addressed.
As with any reporting by the media, objectivity and thorough completeness of the topic discussed in a press release is a necessary requirement with any publishing that is potentially exposed to so many others- more so with such medical issues in particular.

“The public has a lot at stake, and the media has a responsibility always to be aware of the source of information and the conflicts those sources might have when they report the results of clinical research. People who have financial stake in the results of clinical research can well be biased in the way research is conducted, in the way they report it, and what they say about it when interviewed by the media.” – Arnold Relman, former editor in chief of the New England Journal of Medicine

Dan Abshear

It's disheartening to read Daniel Haszard(commenter)is not receiving any form of restitution from Lilly. My daughter never was dx with diabetes, but suffered weight gain, ocular eye dysfunction (that caused inability to read and have to leave junior high early day in and day out); it is the one drug that I believe caused permanent neurological damage to her brain. It is with much grief and sick feeling to listen to that news report.

I only WISH I KNEW NOW WHAT I DIDN'T KNOW IN 1999. LILLY HID THE DOCUMENTS. I feel this is beyond a crime, it is a tragedy without an ending.A permanent abyss.

Why doesn't the justice department take into account just how much (36billion!!?!!) lilly made off the drug and actually fine them an amount that would cause them enough hurt as a company to do anything to discourage this type of behavior. The fines companies get for committing a crime should be in proportion to the amount of money committing that crime made them. Lilly should have to pay at least 15Billion because they *might* feel that. 1.4 billion though? if it's that cheap to deal with this sort of crime (plus whatever millions they spent on lawyers) then what is to keep them from doing this over and over and over??? it costs them 4% maybe after all other costs 5% of the money they made off this crime to take care of the criminal charges and fines? They're just going to do it again. Especialy when the media is mostly ignoring what should be a headline, so what does lilly care? they aren't getting much bad press at all and it cost them nothing.
The mainstream media in this country is total crap.